An Interview with
Yuen Long Eye Centre (Group)
Founder & Chairman
Yuen Long Eye Centre was founded in 2011; thru the years we have operated with the fundamental principle that quality specialist healthcare need not be expensive & must be close to the community. We have been investing/expanding steadily on the core medical Ophthalmic technologies; today we have 4 clinics within the group - 2 in Yuen Long, 1 in Tsuen Wan, and a full scale innovative refractive centre in Kwai Fong.
26 December 2019
Tell us about your background, and how you came to found your company?
Originally trained in England as an applied computer scientist. I have always had a passion in the application of technologies to benefit users/human. The Ophthalmic speciality is family business-related, my role at this healthcare profession is mainly as an investor, business owner and manager. Management team & doctors are all hired externally.
What is most important to you and your organization – mission, vision, or core values? Why?
Core value - always invest in core medical technologies; quality healthcare need not be expensive. We have & never will house our clinics in the top class commercial districts, allows us to stay closer to the community
Can you explain briefly how your service(s)/product(s) works?
We can take on almost all Ophthalmic conditions, from the cornea to the retina, in short!
How has the industry been changing in recent years?
Healthcare is one that doesn't change rapidly, due to the sensitive nature. All medical technologies need to be tested extensively with a significant volume of data. The real change is with us incorporating Presbyond into Hong Kong in 2018, a first in Hong Kong.
What makes you different from what’s currently available in the market?
Presbyond Laser Blended Vision is an exclusive offering available only with our Ophthalmic group; a complex technique to take on Presbyopic conditions of the human eye.
What does the future hold for your company?
We see continued expansion across key densely populated, key community areas of Hong Kong; and continue to invest only in core medical technologies to uphold our key operating principles.